Given the frequent mutation of ARID1A in various cancers including NSCLC, we speculated that some key target genes might be derepressed upon ARID1A loss and contribute to the progression and drug resistance of ARID1A-mutated NSCLC. This evidence concerns the gene ARID1A and cancer.